{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:22:49Z","timestamp":1778685769430,"version":"3.51.4"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2018,12]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>The direct acting antivirals (DAA<\/jats:styled-content>s) for treatment of hepatitis C virus (HCV<\/jats:styled-content>) infection have sustained virologic response (SVR<\/jats:styled-content>) rates of greater than 90% in most patients. However, data evaluating DAA<\/jats:styled-content> use in transplant patients are limited. The goal of this study was to evaluate the effectiveness and safety of HCV<\/jats:styled-content> treatment in this high\u2010risk population.<\/jats:p><\/jats:sec>Methodology<\/jats:title>This single\u2010center retrospective study included liver, kidney, lung, and\/or heart transplant patients who were treated for HCV<\/jats:styled-content> infection with DAA<\/jats:styled-content>s. The primary objective was to identify drug\u2010drug interactions between DAA<\/jats:styled-content>s and immunosuppressants by comparing immunosuppression dosages and levels at baseline and week 4 of HCV<\/jats:styled-content> treatment. As secondary objectives, we described the percentage of patients with new or worsening rejection and\/or graft dysfunction during HCV<\/jats:styled-content> treatment, and the percentage of study patients who achieved SVR<\/jats:styled-content>.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 108 patients included, the majority had liver (76%) or kidney (13%) transplants. Simeprevir plus sofosbuvir was the most commonly prescribed HCV<\/jats:styled-content> treatment (33.9%) and tacrolimus was the most common immunosuppressant (91%). We did not detect a statistically significant difference in immunosuppression dosages or levels during HCV<\/jats:styled-content> treatment. Furthermore, only one patient (<1%) experienced rejection and five patients (4.6%) had six episodes of graft dysfunction while on DAA<\/jats:styled-content>s. Efficacy was high with 98% of patients achieving SVR<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>DAAs appear to be safe and effective for HCV<\/jats:styled-content> treatment in patients with a history of liver and\/or kidney transplantation. More data are needed to evaluate DAA<\/jats:styled-content>s in lung and\/or heart transplant patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12972","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T11:08:45Z","timestamp":1533640125000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8958-6882","authenticated-orcid":false,"given":"Marlina","family":"Mansour","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services UC San Diego Health La Jolla California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Hepatology UC San Diego Health San Diego California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Kerr","sequence":"additional","affiliation":[{"name":"Abdominal Transplantation UC San Diego Health La Jolla California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"AASLD\u2010IDSA.Recommendations for testing managing and treating hepatitis C.http:\/\/www.hcvguidelines.org. Accessed May 5 2017."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28446"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408921"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","unstructured":"ReauN KwoPY RheeS.MAGELLAN\u20102: Safety and Efficacy of Glecaprevir\/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1\u20106 Infection. Presented at: EASL International Liver Meeting; April 19\u201023 2017.","DOI":"10.1016\/S0168-8278(17)30444-0"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12524"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24366"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27770"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-1205"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.09.047"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13518"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13620"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2015.06.003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21123"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2011.06.003"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00868.x"},{"key":"e_1_2_7_18_1","unstructured":"SpachDH.HCV Epidemiology in the United States.https:\/\/www.hepatitisc.uw.edu\/pdf\/screening-diagnosis\/epidemiology-us\/core-concept\/all. Accessed June 1 2017."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00052-9"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29258"},{"key":"e_1_2_7_21_1","unstructured":"Prograf\u00ae [package insert].Northbrook IL:Astellas Pharma US Inc.;2015."},{"key":"e_1_2_7_22_1","unstructured":"Sandimmune\u00ae [package insert].East Hanover NJ:Novartis Pharmaceuticals Corporation;2015."},{"key":"e_1_2_7_23_1","unstructured":"Neoral\u00ae [package insert].East Hanover NJ:Novartis Pharmaceuticals Corporation;2015."},{"key":"e_1_2_7_24_1","unstructured":"CellCept\u00ae [package insert].South San Francisco CA:Genentech USA Inc.;2015."},{"key":"e_1_2_7_25_1","unstructured":"Myfortic\u00ae [package insert].East Hanover NJ:Novartis Pharmaceuticals Corporation;2016."},{"key":"e_1_2_7_26_1","unstructured":"Rapamune\u00ae [package insert].Philadelphia PA:Pfize Inc.;2011."},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29723"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29704"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002033"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2016.09.058"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T02:25:49Z","timestamp":1694744749000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/tid.12972"],"URL":"https:\/\/doi.org\/10.1111\/tid.12972","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,22]]},"assertion":[{"value":"2018-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12972"}}